EXCHANGE TRADED CONCEPTS TRUST
ROBO Global® Healthcare Technology and Innovation ETF
ROBO Global® Robotics and Automation Index ETF
ROBO Global® Artificial Intelligence ETF
Annual Report
April 30, 2022
ROBO Global®
Healthcare Technology and Innovation ETF
Robotics and Automation Index ETF
Artificial Intelligence ETF
Table of Contents
1 | ||
10 | ||
17 | ||
18 | ||
19 | ||
21 | ||
22 | ||
34 | ||
35 | ||
38 | ||
39 | ||
40 | ||
Board Consideration and Approval of Advisory and Sub-Advisory Agreements |
41 | |
47 |
The Funds file their complete schedule of investments with the U.S. Securities and Exchange Commission (the “Commission”) for the first and third quarters of each fiscal year as an exhibit to each Fund’s report on Form N-PORT within sixty days after the end of the period. Each Fund’s Form N-PORT reports are available on the Commission’s website at http://www.sec.gov.
Exchange Traded Concepts, LLC’s proxy voting policies and procedures are attached to each Fund’s Statement of Additional Information (the “SAI”). The SAI, as well as information relating to how each Fund voted proxies relating to each Fund’s securities during the most recent 12-month period ended June 30, is available without charge, upon request, by calling (855)-456-ROBO and on the Commission’s website at http://www.sec.gov.
ROBO Global®
Healthcare Technology and Innovation ETF
Dear Shareholders,
On behalf of the entire team, we want to express our appreciation for the confidence you have placed in the ROBO Global® Healthcare Technology and Innovation ETF (“HTEC” or the “Fund”). The following information pertains to the fiscal year May 1, 2021 through April 30, 2022.
The Fund seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the ROBO Global® Healthcare Technology and Innovation Index (the “Index”). The Index provides investors with unique, global exposure to companies leading the healthcare technology revolution across the following sub-sectors: (1) diagnostics, (2) lab process automation, (3) regenerative medicine, (4) precision medicine, (5) data and analytics, (6) telehealth, (7) robotics; (8) medical instruments; and (9) genomics.
Despite generally positive performance throughout most of 2021, the fund experienced headwinds to performance as we entered 2022. Concerns over inflation, slowing economic growth and the expectation of rising interest rates caused the market to shift out of growth and technology-oriented companies held by the Fund in favor of more defensive/value securities.
The Fund had negative performance during the fiscal year ended April 30, 2022. The market price for HTEC decreased 33.63% and the NAV decreased 33.33%, while the MSCI ACWI Index, a broad market index, decreased 5.44% over the same period. The Fund’s Index returned negative 32.96%.
The Fund commenced operations on June 24, 2019 and had 4,200,001 shares outstanding on April 30, 2022.
Thank you for your investment in HTEC.
Sincerely,
J. Garrett
Stevens
Chief Executive Officer
Exchange Traded Concepts, LLC, Adviser to
the Fund
1
ROBO Global®
Healthcare Technology and Innovation ETF
Management Discussion of Fund Performance (Unaudited) (Continued)
About the Index: The Fund tracks the Index, which is designed to measure the performance of robotics-related and/or automation-related companies. The Index consists of securities of both U.S. and foreign issuers, including securities of issuers located in emerging market countries.
The Fund is designed to track, before fees and expenses, the price and yield performance of the Index. This is a rule-based index which employs specific investment criteria focused on companies that derive a portion of revenues and profits from robotics-related and/or automation-related products and/or services.
The S&P 500 Index is a market-value weighted index consisting of 500 stocks chosen for market size, liquidity, and industry group representation, with each stock’s weight in the S&P 500 Index proportionate to its market value. The MSCI ACWI Index (All Country World Index) is a free float-adjusted market capitalization weighted index that is designed to measure the equity market performance of developed and emerging markets. The MSCI ACWI Index consists of 47 country indices comprising 23 developed markets and 24 emerging markets country indices.
This material represents an assessment of the market environment at a specific point in time and is not intended to be a forecast of future events, or a guarantee of future results. This information should not be relied upon by the reader as research or investment advice.
Growth of a $10,000 Investment
(at Net Asset Value)
AVERAGE ANNUAL TOTAL RETURN
FOR | ||||||||
1 Year |
Annualized Inception to Date* | |||||||
Net Asset Value |
Market Price |
Net Asset Value |
Market Price | |||||
ROBO Global® Healthcare Technology and Innovation ETF |
-33.33% |
-33.63% |
8.84% |
8.71% | ||||
ROBO Global® Healthcare Technology and Innovation Index |
-32.96% |
-32.96% |
9.57% |
9.57% | ||||
S&P 500® Index |
0.21% |
0.21% |
14.48% |
14.48% | ||||
MSCI ACWI Index |
-5.44% |
-5.44% |
9.87% |
9.87% |
*Fund commenced operations on June 24, 2019.
2
ROBO Global®
Healthcare Technology and Innovation ETF
Management Discussion of Fund Performance (Unaudited) (Concluded)
The performance data quoted herein represents past performance and the return and value of an investment in the Fund will fluctuate so that shares, when redeemed or sold in the market, may be worth more or less than their original cost. Past performance is no guarantee of future performance and should not be considered as a representation of the future results of the Fund. The Fund’s performance assumes the reinvestment of all dividends and all capital gains. Index returns assume reinvestment of dividends and, unlike the Fund’s returns, do not reflect any fees or expenses. If such fees and expenses were included in the Index returns, the performance would have been lower. Please note that one cannot invest directly in an unmanaged index.
Investors should consider the investment objectives, risks, charges and expenses of the Fund carefully before investing. A prospectus, containing this and other information, is available at www.roboglobaletfs.com. Investors should read the prospectus carefully before investing. There are risks associated with investing, including possible loss of principal.
Current performance may be lower or higher than the performance data shown above.
Performance data current to the most recent month-end is available at www.roboglobaletfs.com.
There are no assurances that the Fund will meet its stated objective.
The Fund’s holdings and allocations are subject to change and should not be considered recommendations to buy individual securities.
Returns shown do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or the redemption of Fund shares.
3
ROBO Global®
Robotics and Automation Index ETF
Management Discussion of Fund Performance (Unaudited)
Dear Shareholders,
On behalf of the entire team, we want to express our appreciation for the confidence you have placed in the ROBO Global® Robotics and Automation Index ETF (“ROBO” or the “Fund”). The following information pertains to the fiscal year May 1, 2021, through April 30, 2022.
The Fund seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the ROBO Global® Robotics and Automation Index (the “Index”). The Index provides investors with a comprehensive and diversified benchmark that represents the global value chain of robotics, automation, and enabling technologies. This value chain includes not only large, well established companies, but also providers of both the key enabling technologies (e.g., sensing, computing, machine learning, actuation, etc.) and the applications that deliver capabilities in every industry (e.g., factory automation, surgical robotics, food and agriculture, 3D printing, logistics automation, and more).
Despite generally positive performance throughout most of 2021, the fund experienced headwinds to performance as we entered 2022. Concerns over inflation, slowing economic growth and the expectation of rising interest rates caused the market to shift out of growth and technology-oriented companies in favor of more defensive/value securities.
The Fund had negative performance during the fiscal year ended April 30, 2022. The market price for ROBO decreased 22.05% and the NAV decreased 21.35%, while the MSCI ACWI Index, a broad market index, decreased 5.44% over the same period. The Fund’s Index decreased 20.76%.
The Fund commenced operations on October 21, 2013 and had 27,400,000 shares outstanding on April 30, 2022.
Thank you for your investment in ROBO.
Sincerely,
J. Garrett
Stevens
Chief Executive Officer
Exchange Traded Concepts, LLC, Adviser to
the Fund
4
ROBO Global®
Robotics and Automation Index ETF
Management Discussion of Fund Performance (Unaudited) (Continued)
About the Index: The Fund tracks the Index, which is designed to measure the performance of robotics-related and/or automation-related companies. The Index consists of securities of both U.S. and foreign issuers, including securities of issuers located in emerging market countries.
The Fund is designed to track, before fees and expenses, the price and yield performance of the Index. This is a rule-based index which employs specific investment criteria focused on companies that derive a portion of revenues and profits from robotics-related and/or automation-related products and/or services.
The S&P 500 Index is a market-value weighted index consisting of 500 stocks chosen for market size, liquidity, and industry group representation, with each stock’s weight in the S&P 500 Index proportionate to its market value. The MSCI ACWI Index (All Country World Index) is a free float-adjusted market capitalization weighted index that is designed to measure the equity market performance of developed and emerging markets. The MSCI ACWI Index consists of 47 country indices comprising 23 developed markets and 24 emerging markets country indices.
This material represents an assessment of the market environment at a specific point in time and is not intended to be a forecast of future events, or a guarantee of future results. This information should not be relied upon by the reader as research or investment advice.
Growth of a $10,000 Investment
(at Net Asset Value)
AVERAGE ANNUAL TOTAL RETURN
FOR | ||||||||||||
1 Year |
5 Year |
Annualized | ||||||||||
Net Asset Value |
Market Price |
Net Asset Value |
Market Price |
Net Asset Value |
Market Price | |||||||
ROBO Global® Robotics & Automation Index ETF |
-21.35% |
-22.05% |
9.21% |
8.99% |
8.90% |
8.80% | ||||||
ROBO Global® Robotics & Automation Index |
-20.76% |
-20.76% |
9.93% |
9.93% |
9.97% |
9.97% | ||||||
S&P 500® Index |
0.21% |
0.21% |
13.66% |
13.66% |
12.79% |
12.79% | ||||||
MSCI ACWI Index |
-5.44% |
-5.44% |
9.46% |
9.46% |
8.03% |
8.03% |
*Fund commenced operations on October 21, 2013.
5
ROBO Global®
Robotics and Automation Index ETF
Management Discussion of Fund Performance (Unaudited) (Concluded)
The performance data quoted herein represents past performance and the return and value of an investment in the Fund will fluctuate so that shares, when redeemed or sold in the market, may be worth more or less than their original cost. Past performance is no guarantee of future performance and should not be considered as a representation of the future results of the Fund. The Fund’s performance assumes the reinvestment of all dividends and all capital gains. Index returns assume reinvestment of dividends and, unlike the Fund’s returns, do not reflect any fees or expenses. If such fees and expenses were included in the Index returns, the performance would have been lower. Please note that one cannot invest directly in an unmanaged index.
Investors should consider the investment objectives, risks, charges and expenses of the Fund carefully before investing. A prospectus, containing this and other information, is available at www.roboglobaletfs.com. Investors should read the prospectus carefully before investing. There are risks associated with investing, including possible loss of principal.
Current performance may be lower or higher than the performance data shown above.
Performance data current to the most recent month-end is available at www.roboglobaletfs.com.
There are no assurances that the Fund will meet its stated objective.
The Fund’s holdings and allocations are subject to change and should not be considered recommendations to buy individual securities.
Returns shown do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or the redemption of Fund shares.
6
ROBO Global®
Artificial Intelligence ETF
Management Discussion of Fund Performance (Unaudited)
Dear Shareholders,
On behalf of the entire team, we want to express our appreciation for the confidence you have placed in the ROBO Global® Artificial Intelligence ETF (“THNQ” or the “Fund”). The following information pertains to the fiscal year May 1, 2021 through April 30, 2022.
The Fund seeks provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the ROBO Global® Artificial Intelligence Index (the “Index”). The Index provides investors with unique, global exposure to companies that are actively developing and leveraging artificial intelligence-based tools and artificial intelligence-powered engines to capitalize on new market opportunities and accelerate their revenue growth.
Despite generally positive performance throughout most of 2021, the fund experienced headwinds to performance as we entered 2022. Concerns over inflation, slowing economic growth and the expectation of rising interest rates caused the market to shift out of growth and technology-oriented companies in favor of more defensive/value securities.
The Fund had negative performance during the fiscal period ended April 30, 2022. The market price for THNQ decreased 25.85% and the NAV decreased 25.40% while the MSCI ACWI Index, a broad market index, decreased 5.44% over the same period. The Fund’s Index returned negative 25.17%.
The Fund commenced operations on May 8, 2020 and had 950,000 shares outstanding on April 30, 2022.
Thank you for your investment in THNQ.
Sincerely,
J. Garrett
Stevens
Chief Executive Officer
Exchange Traded Concepts, LLC, Adviser to
the Fund
7
ROBO Global®
Artificial Intelligence ETF
Management Discussion of Fund Performance (Unaudited) (Continued)
About the Index: The Fund tracks the Index, which is designed to measure the performance of Artificial Intelligence-related companies. The Index consists of securities of both U.S. and foreign issuers, including securities of issuers located in emerging market countries.
The Fund is designed to track, before fees and expenses, the price and yield performance of the Index. This is a rule-based index which employs specific investment criteria focused on companies that derive a portion of revenues and profits from robotics-related and/or automation-related products and/or services.
The S&P 500 Index is a market-value weighted index consisting of 500 stocks chosen for market size, liquidity, and industry group representation, with each stock’s weight in the S&P 500 Index proportionate to its market value. The MSCI ACWI Index (All Country World Index) is a free float-adjusted market capitalization weighted index that is designed to measure the equity market performance of developed and emerging markets. The MSCI ACWI Index consists of 47 country indices comprising 23 developed markets and 24 emerging markets country indices.
This material represents an assessment of the market environment at a specific point in time and is not intended to be a forecast of future events, or a guarantee of future results. This information should not be relied upon by the reader as research or investment advice.
Growth of a $10,000 Investment
(at Net Asset Value)
AVERAGE ANNUAL TOTAL RETURN
FOR | ||||||||
1 Year |
Annualized Inception to Date* | |||||||
Net Asset Value |
Market Price |
Net Asset Value |
Market Price | |||||
ROBO Global® Artificial Intelligence ETF |
-25.40% |
-25.85% |
11.26% |
11.09% | ||||
ROBO Global® Artificial Intelligence Index |
-25.17% |
-25.17% |
11.76% |
11.76% | ||||
S&P 500® Index |
0.21% |
0.21% |
20.80% |
20.80% | ||||
MSCI ACWI Index |
-5.44% |
-5.44% |
17.44% |
17.44% |
*Fund commenced operations on May 8, 2020.
8
ROBO Global®
Artificial Intelligence ETF
Management Discussion of Fund Performance (Unaudited) (Concluded)
The performance data quoted herein represents past performance and the return and value of an investment in the Fund will fluctuate so that shares, when redeemed or sold in the market, may be worth more or less than their original cost. Past performance is no guarantee of future performance and should not be considered as a representation of the future results of the Fund. The Fund’s performance assumes the reinvestment of all dividends and all capital gains. Index returns assume reinvestment of dividends and, unlike the Fund’s returns, do not reflect any fees or expenses. If such fees and expenses were included in the Index returns, the performance would have been lower. Please note that one cannot invest directly in an unmanaged index.
Investors should consider the investment objectives, risks, charges and expenses of the Fund carefully before investing. A prospectus, containing this and other information, is available at www.roboglobaletfs.com. Investors should read the prospectus carefully before investing. There are risks associated with investing, including possible loss of principal.
Current performance may be lower or higher than the performance data shown above.
Performance data current to the most recent month-end is available at www.roboglobaletfs.com.
There are no assurances that the Fund will meet its stated objective.
The Fund’s holdings and allocations are subject to change and should not be considered recommendations to buy individual securities.
Returns shown do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or the redemption of Fund shares.
9
Description |
Shares |
Fair Value | |||
COMMON STOCK — 100.0% |
|
||||
Australia — 1.2% |
|
||||
Health Care — 1.2% |
|
||||
CSL |
8,301 |
$ |
1,612,228 | ||
Total Australia |
|
1,612,228 | |||
Belgium — 0.8% |
|
||||
Information Technology — 0.8% |
|
||||
Materialise ADR* |
68,772 |
|
1,072,843 | ||
Total Belgium |
|
1,072,843 | |||
China — 1.4% |
|
||||
Consumer Discretionary — 1.4% |
|
||||
Ping An Healthcare and Technology* |
698,800 |
|
1,754,537 | ||
Total China |
|
1,754,537 | |||
Denmark — 0.8% |
|
||||
Health Care — 0.8% |
|
||||
GN Store Nord |
25,621 |
|
976,689 | ||
Total Denmark |
|
976,689 | |||
France — 1.2% |
|
||||
Health Care — 1.2% |
|
||||
Eurofins Scientific |
16,891 |
|
1,580,920 | ||
Total France |
|
1,580,920 | |||
Germany — 1.4% |
|
||||
Health Care — 1.4% |
|
||||
Siemens Healthineers |
33,884 |
|
1,832,340 | ||
Total Germany |
|
1,832,340 | |||
Hong Kong — 2.3% |
|
||||
Consumer Discretionary — 2.3% |
|
||||
Alibaba Health Information Technology* |
2,652,000 |
|
1,537,901 | ||
JD Health International* |
230,900 |
|
1,487,608 | ||
Total Consumer Discretionary |
|
3,025,509 | |||
Total Hong Kong |
|
3,025,509 | |||
Italy — 1.5% |
|
||||
Health Care — 1.5% |
|
||||
DiaSorin |
14,724 |
|
1,942,417 | ||
Total Italy |
|
1,942,417 |
Description |
Shares |
Fair Value | |||
Japan — 0.8% |
|
||||
Health Care — 0.8% |
|
||||
Terumo |
34,200 |
$ |
1,027,901 | ||
Total Japan |
|
1,027,901 | |||
Netherlands — 1.2% |
|
||||
Health Care — 1.2% |
|
||||
Koninklijke Philips |
58,793 |
|
1,550,596 | ||
Total Netherlands |
|
1,550,596 | |||
Spain — 1.1% |
|
||||
Health Care — 1.1% |
|
||||
Grifols |
84,598 |
|
1,427,950 | ||
Total Spain |
|
1,427,950 | |||
Switzerland — 3.7% |
|
||||
Health Care — 3.7% |
|
||||
Lonza Group |
2,782 |
|
1,657,764 | ||
Roche Holding |
4,582 |
|
1,710,727 | ||
Tecan Group |
4,581 |
|
1,395,089 | ||
Total Health Care |
|
4,763,580 | |||
Total Switzerland |
|
4,763,580 | |||
United Kingdom — 2.0% |
|
||||
Health Care — 2.0% |
|
||||
EMIS Group |
69,466 |
|
1,166,924 | ||
Smith & Nephew PLC |
89,052 |
|
1,456,808 | ||
Total Health Care |
|
2,623,732 | |||
Total United Kingdom |
|
2,623,732 | |||
United States — 80.6% |
|
||||
Health Care — 78.9% |
|
||||
Abbott Laboratories |
11,253 |
|
1,277,216 | ||
ABIOMED* |
6,703 |
|
1,920,946 | ||
Agilent Technologies |
12,555 |
|
1,497,435 | ||
Akoya Biosciences* |
187,887 |
|
1,768,017 | ||
Align Technology* |
3,670 |
|
1,063,970 | ||
Alnylam Pharmaceuticals* |
12,772 |
|
1,704,168 | ||
Arrowhead Pharmaceuticals* |
48,934 |
|
2,011,677 | ||
Avanos Medical* |
36,570 |
|
1,066,381 | ||
Axogen* |
231,549 |
|
1,676,415 | ||
Azenta |
25,228 |
|
1,891,091 | ||
Baxter International |
15,506 |
|
1,101,856 | ||
Becton Dickinson |
4,300 |
|
1,062,917 | ||
BioMarin Pharmaceutical* |
18,716 |
|
1,522,547 | ||
Bio-Rad Laboratories, Cl A* |
3,105 |
|
1,589,946 | ||
Boston Scientific* |
47,777 |
|
2,011,888 | ||
Bristol-Myers Squibb |
18,630 |
|
1,402,280 | ||
Butterfly Network* |
337,060 |
|
1,122,410 | ||
Cardiovascular Systems* |
90,982 |
|
1,701,363 | ||
CareDx* |
58,167 |
|
1,770,603 | ||
Catalent* |
19,359 |
|
1,753,151 | ||
Cerus* |
221,764 |
|
1,024,550 |
The accompanying notes are an integral part of the financial statements.
10
ROBO Global®
Healthcare Technology and Innovation ETF
Schedule of Investments
April 30, 2022 (Concluded)
Description |
Shares |
Fair Value | |||
Charles River Laboratories International* |
7,560 |
$ |
1,825,816 | ||
Codexis* |
82,702 |
|
994,905 | ||
CONMED |
9,120 |
|
1,212,595 | ||
Danaher |
7,520 |
|
1,888,498 | ||
DexCom* |
4,870 |
|
1,989,784 | ||
Editas Medicine, Cl A* |
65,386 |
|
865,711 | ||
Edwards Lifesciences* |
13,952 |
|
1,475,843 | ||
Exact Sciences* |
27,323 |
|
1,504,131 | ||
Fate Therapeutics* |
32,344 |
|
923,745 | ||
Fulgent Genetics* |
35,892 |
|
1,969,753 | ||
Glaukos* |
38,648 |
|
1,827,664 | ||
Globus Medical, Cl A* |
15,356 |
|
1,016,874 | ||
Guardant Health* |
33,364 |
|
2,058,559 | ||
Health Catalyst* |
78,374 |
|
1,304,143 | ||
Hologic* |
22,106 |
|
1,591,411 | ||
Illumina* |
6,497 |
|
1,927,335 | ||
Incyte* |
27,584 |
|
2,067,697 | ||
Insulet* |
8,032 |
|
1,919,568 | ||
Integra
LifeSciences |
31,090 |
|
1,901,464 | ||
Intuitive Surgical* |
6,951 |
|
1,663,374 | ||
IQVIA Holdings* |
8,420 |
|
1,835,476 | ||
iRhythm Technologies* |
14,949 |
|
1,844,258 | ||
Masimo* |
10,324 |
|
1,166,302 | ||
Medpace Holdings* |
11,195 |
|
1,495,316 | ||
Moderna* |
14,162 |
|
1,903,514 | ||
NanoString Technologies* |
44,466 |
|
835,071 | ||
Natera* |
37,187 |
|
1,306,007 | ||
NeoGenomics* |
98,983 |
|
935,389 | ||
Nevro* |
25,384 |
|
1,565,939 | ||
Novocure* |
30,241 |
|
2,315,855 | ||
Omnicell* |
14,039 |
|
1,532,638 | ||
Penumbra* |
9,055 |
|
1,562,531 | ||
PerkinElmer |
9,825 |
|
1,440,443 | ||
Quidel* |
17,620 |
|
1,772,924 | ||
Regeneron Pharmaceuticals* |
3,120 |
|
2,056,423 | ||
STAAR Surgical* |
26,832 |
|
1,531,839 | ||
Stryker |
6,295 |
|
1,518,732 | ||
Tabula Rasa HealthCare* |
176,667 |
|
595,368 | ||
Tactile Systems Technology* |
77,145 |
|
1,302,208 | ||
Teladoc Health* |
31,450 |
|
1,061,752 | ||
Thermo Fisher Scientific |
3,845 |
|
2,125,978 | ||
Twist Bioscience* |
43,622 |
|
1,258,058 | ||
Veeva Systems, Cl A* |
11,195 |
|
2,036,931 | ||
Veracyte* |
84,828 |
|
1,736,429 | ||
Vertex Pharmaceuticals* |
6,603 |
|
1,804,072 | ||
|
102,409,150 |
Description |
Shares |
Fair Value | |||
Information Technology — 1.7% |
|
||||
3D Systems* |
88,406 |
$ |
1,002,524 | ||
Novanta* |
9,338 |
|
1,201,801 | ||
|
2,204,325 | ||||
Total United States |
|
104,613,475 | |||
Total
Common Stock |
|
129,804,717 | |||
SHORT-TERM INVESTMENT — 0.0% |
|
||||
Invesco Government & Agency, Cl Institutional, 0.35%(A) |
49,917 |
|
49,917 | ||
Total
Short-Term Investment |
|
49,917 | |||
Total
Investments — 100.0% |
$ |
129,854,634 |
Percentages are based on Net Assets of $129,833,494.
* Non-income producing security.
(A) Rate shown is the 7-day effective yield as of April 30, 2022.
ADR — American Depositary Receipt
Cl — Class
PLC — Public Limited Company
As of April 30, 2022, all of the Fund’s investments were considered Level 1 of the fair value hierarchy, in accordance with the authoritative guidance under U.S. GAAP.
The accompanying notes are an integral part of the financial statements.
11
ROBO Global®
Robotics and Automation Index ETF
Schedule of Investments
April 30, 2022
Description |
Shares |
Fair Value | |||
COMMON STOCK — 99.7% |
|
||||
Belgium — 1.5% |
|
||||
Information Technology — 1.5% |
|
||||
Materialise ADR* (A) |
1,300,003 |
$ |
20,280,047 | ||
Total Belgium |
|
20,280,047 | |||
Canada — 1.3% |
|
||||
Industrials — 1.3% |
|
||||
ATS Automation Tooling Systems* |
630,987 |
|
18,509,215 | ||
Total Canada |
|
18,509,215 | |||
China — 1.0% |
|
||||
Industrials — 0.7% |
|
||||
Han’s Laser Technology Industry Group, Cl A |
796,459 |
|
3,361,403 | ||
Shenzhen Inovance Technology, Cl A |
427,959 |
|
3,748,783 | ||
Siasun Robot & Automation, Cl A* |
2,926,487 |
|
3,403,202 | ||
|
10,513,388 | ||||
Information Technology — 0.3% |
|
||||
Iflytek |
767,524 |
|
4,311,278 | ||
Total China |
|
14,824,666 | |||
Finland — 1.4% |
|
||||
Industrials — 1.4% |
|
||||
Cargotec, Cl B |
544,459 |
|
19,057,874 | ||
Total Finland |
|
19,057,874 | |||
France — 2.4% |
|
||||
Industrials — 1.1% |
|
||||
Schneider Electric |
103,538 |
|
15,040,650 | ||
Information Technology — 1.3% |
|
||||
Dassault Systemes |
410,755 |
|
18,431,564 | ||
Total France |
|
33,472,214 |
Description |
Shares |
Fair Value | |||
Germany — 7.4% |
|
||||
Industrials — 6.2% |
|
||||
Duerr |
562,683 |
$ |
14,745,119 | ||
GEA Group |
587,958 |
|
23,055,352 | ||
KION Group |
187,122 |
|
10,513,781 | ||
Krones |
271,548 |
|
21,241,768 | ||
Siemens |
129,590 |
|
16,101,856 | ||
|
85,657,876 | ||||
Information Technology — 1.2% |
|
||||
Jenoptik |
578,501 |
|
16,441,241 | ||
Total Germany |
|
102,099,117 | |||
Japan — 20.7% |
|
||||
Industrials — 14.6% |
|
||||
Daifuku |
339,417 |
|
21,089,124 | ||
Daihen |
386,109 |
|
11,115,982 | ||
FANUC |
144,928 |
|
22,556,909 | ||
Fuji Machine Manufacturing |
1,149,000 |
|
19,351,019 | ||
Harmonic Drive Systems(A) |
681,839 |
|
17,367,001 | ||
Mitsubishi Electric |
1,147,844 |
|
12,119,872 | ||
Nabtesco |
686,510 |
|
15,779,768 | ||
Shibaura Machine |
531,733 |
|
12,784,411 | ||
SMC |
37,676 |
|
18,334,917 | ||
THK |
865,157 |
|
17,321,837 | ||
Toyota Industries |
278,300 |
|
16,733,228 | ||
Yaskawa Electric |
556,449 |
|
19,112,365 | ||
|
203,666,433 | ||||
Information Technology — 6.1% |
|
||||
Amano |
785,600 |
|
15,213,572 | ||
Keyence |
53,048 |
|
21,639,293 | ||
Omron |
311,258 |
|
18,561,125 | ||
Optex Group |
759,000 |
|
10,087,975 | ||
Yokogawa Electric |
1,239,078 |
|
19,921,268 | ||
|
85,423,233 | ||||
Total Japan |
|
289,089,666 | |||
Norway — 0.9% |
|
||||
Industrials — 0.9% |
|
||||
AutoStore Holdings*(A) |
5,635,509 |
|
12,944,694 | ||
Total Norway |
|
12,944,694 | |||
South Korea — 1.3% |
|
||||
Information Technology — 1.3% |
|
||||
Koh Young Technology |
1,219,280 |
|
18,784,290 | ||
Total South Korea |
|
18,784,290 |
The accompanying notes are an integral part of the financial statements.
12
ROBO Global®
Robotics and Automation Index ETF
Schedule of Investments
April 30, 2022 (Continued)
Description |
Shares |
Fair Value | |||
Sweden — 2.7% |
|
||||
Health Care — 0.9% |
|
||||
Elekta, Cl B(A) |
1,759,961 |
$ |
11,993,832 | ||
Information Technology — 1.8% |
|
||||
Hexagon, Cl B(A) |
1,933,464 |
|
25,369,268 | ||
Total |